President Trump announcing a deal with Fizer. The drug maker will be selling medication directly to consumers through a new website that's called Trump RX. The company won't face Pharma specific tariffs as long as it invests in US manufacturing.Joining us right now is John Lamatina. He is a senior partner at Pure Tech Health and he's also the author of multiple books on the industry including Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. He's also the former president of Fizer Global ...

辉瑞(PFE.US)股价走高，截至发稿，该股涨超2.3%，报24.4美元。消息面上，美国总统特朗普宣布与辉 瑞公司的药品定价协议，将自愿通过医疗补助计划以更低价格销售其药物。 ...

Last year, animal rights group PETA urged securities regulators to investigate Charles River Laboratories for allegedly misleading investors about its sales and purchases of long-tailed macaques, widely used in pharmaceutical research. The company faced accusations of importing thousands of non-human primates illegally and sourcing some from firms linked to an international smuggling ring, as well as falsely labeling monkeys sold to clients. Charles River Laboratories International Inc. CRL stock is trading ...

Group 1 - The core claim made by President Trump is that the U.S. government has reduced prescription drug prices by as much as 1500%, which is mathematically impossible according to multiple media outlets [1][3] - Media reports highlight that a reduction of 100% would mean drugs are free, and a reduction exceeding 100% implies that pharmaceutical companies would pay consumers to take the drugs [3] - The White House spokesperson stated that Americans pay significantly more for the same medications compared to other developed countries, asserting that the Trump administration has made substantial efforts to alleviate this burden [3] Group 2 - Trump has threatened to impose high tariffs on imported drugs, claiming this would lower drug prices and enhance national security [3] - Industry professionals express skepticism regarding the feasibility of achieving these goals due to the complexities of the supply chain and high domestic production costs [3] - The tariff policy introduces additional uncertainty for the U.S. pharmaceutical industry and companies operating within it [3]

Core Viewpoint - President Trump claimed that the U.S. government has reduced prescription drug prices by up to 1500%, a statement that has been widely criticized by media outlets as mathematically impossible [1][3]. Group 1: Drug Pricing Claims - Trump stated that drug prices have been lowered by 1200%, 1300%, 1400%, and 1500%, emphasizing that these figures are not mere percentages like 50% [3]. - Media outlets pointed out that a 100% price reduction would mean drugs are free, while a reduction exceeding 100% implies that pharmaceutical companies would pay consumers to take the drugs [3]. Group 2: Government Response - White House spokesperson Kush DeSantis defended Trump's claims by stating that Americans pay significantly more for the same medications compared to other developed countries, asserting that the Trump administration has made substantial efforts to alleviate this burden [3]. - The statement reflects a misunderstanding of pricing and percentage operations, potentially undermining public confidence in Trump's ability to address drug pricing issues [3]. Group 3: Tariff Threats and Industry Impact - Trump has threatened to impose high tariffs on imported drugs, claiming this would lower drug prices and enhance national security [3]. - Industry professionals argue that achieving these goals is challenging due to complex supply chains and high domestic production costs, with tariff policies introducing further uncertainty for the U.S. pharmaceutical industry and companies [3].

Core Viewpoint - The outlook for large pharmaceutical companies in the US and Europe in the second half of 2025 is mixed, with concerns over US drug pricing and optimistic expectations for upcoming data releases [2]. Group 1: Patent Expiration Risks - Over $350 billion in annual sales for large pharmaceutical companies in the US and Europe face risks from patent expirations, with 133 drugs losing exclusivity between 2025 and 2030 [5]. - Approximately 40% of the revenue at risk from patent expirations comes from small molecule drugs, while biologics represent the highest share of potential sales erosion [5]. - Merck faces the greatest risk due to the patent expiration of Keytruda in 2028, with Bristol Myers Squibb also significantly impacted [5]. Group 2: Currency Impact - The recent decline of the US dollar may negatively affect non-dollar reporting pharmaceutical companies, including Sanofi, Roche, GSK, and Novo Nordisk [7]. - Conversely, companies like AstraZeneca and Novartis, which report in dollars, may benefit from favorable currency effects [7]. Group 3: Earnings Growth Projections - Eli Lilly and Novo Nordisk are expected to lead in adjusted earnings growth for 2025, with Lilly's operating margin showing significant expansion potential [8]. - AstraZeneca, Sanofi, and Novartis are projected to achieve double-digit earnings growth, with Novartis's outlook being particularly surprising given its patent challenges [8]. - Bristol Myers Squibb and Bayer are experiencing profit margin pressures due to competition from high-margin generics [8]. Group 4: Sales Forecasts - Sales forecasts for major pharmaceutical companies indicate varied growth rates, with Eli Lilly projected to grow from $45.043 billion in 2024 to $100.289 billion by 2029, reflecting a compound annual growth rate (CAGR) of 22.7% [9]. - Novo Nordisk is expected to see sales increase from $290.403 billion in 2024 to $515.458 billion by 2029, with a CAGR of 14.3% [9]. - In contrast, Pfizer's sales are projected to decline from $63.627 billion in 2024 to $53.724 billion by 2029, indicating a negative CAGR of 1.5% [9].

AbbVie (ABBV) FY Conference Summary Industry Overview - The pharmaceutical sector is currently facing challenges related to drug pricing and affordability, with ongoing discussions with the administration aimed at balancing access to medicines and preserving innovation [1][4][7]. - The U.S. is noted to pay significantly more for innovative medicines compared to Europe, which pays about half as much [2]. Core Company Insights Drug Pricing and Administration Engagement - AbbVie is encouraged by productive conversations with the administration regarding drug pricing and affordability [1][5]. - The company is actively engaging in trade negotiations to address disparities in drug pricing and reimbursement timelines, particularly in the EU [2][3]. Financial Performance and Guidance - AbbVie reported strong business momentum, exceeding revenue guidance by $550 million in Q1 2025, with significant contributions from immunology, neuroscience, oncology, and aesthetics [19][21]. - The company raised its full-year sales guidance to approximately $59.7 billion, marking a new peak shortly after the HUMIRA loss of exclusivity [21][22]. Product Performance - The ex-HUMIRA business grew approximately 23% year-over-year on an operational basis, indicating robust performance across various franchises [20][23]. - SKYRIZI and RINVOQ are capturing significant market share in immunology, with one out of every two new switching patients in Crohn's disease opting for these treatments [38][39]. Pipeline and Future Growth - AbbVie has a strong pipeline with a focus on early-stage opportunities, having executed over 25 early-stage deals since the beginning of the previous year [33][34]. - The company is investing in differentiated therapies across various therapeutic areas, including immunology, oncology, and neuroscience, with a particular emphasis on addressing unmet needs in obesity and Parkinson's disease [36][57]. Competitive Landscape - The competitive environment in immunology is intensifying, with new entrants like Tremfya and Stellara biosimilars impacting market dynamics. However, AbbVie maintains a strong position due to the efficacy of SKYRIZI and RINVOQ [38][44]. - The introduction of oral IL-23s is expected to carve out a niche for certain patients, but AbbVie believes that its biologics will continue to dominate the market for more severe cases [47][49]. Aesthetics and Consumer Sentiment - The aesthetics market is showing signs of stabilization, with AbbVie recovering market share in the toxin segment. The company anticipates that the approval of a new fast-acting toxin will further stimulate market growth [75][77]. Key Takeaways - AbbVie is well-positioned for growth with a robust pipeline and strong financial performance, despite challenges in the pharmaceutical landscape related to pricing and competition [15][16]. - The company is focused on maintaining its R&D leadership while navigating regulatory changes and market dynamics [7][30].